Eur Rev Med Pharmacol Sci 2017; 21 (5): 1060-1064

The predictive value of baseline LDL-TG level on major adverse cardiovascular events in a followed up cohort population

X.-H. Ding, P. Ye, X.-N. Wang, R.-H. Cao, X. Yang, W.-K. Xiao, Y. Zhang, Y.-Y. Bai, H.-M. Wu

Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China. yeping301@sina.com


OBJECTIVE: We aimed at identifying the predictive roles of Low-Density Lipoprotein Triglycerides (LDL-TG) for major adverse cardiovascular events (MACEs).

PATIENTS AND METHODS: A longitudinal study in a routine health check-up population was performed with an average follow-up of 4.8 years. The participants involved in this study were 1680, from 2007 to 2009, and all had followed-up for all-cause mortality, cardiovascular disease mortality, and the development of MACEs. The demographic information and anthropometric parameters at baseline were recorded. The baseline and follow-up conventional lipid parameters were measured. We also examined the level LDL-TG, as well as the relationship between its level and MACEs.

RESULTS: MACEs individuals were characterized by statistically higher baseline LDL-TG (17.22 ± 8.05 vs. 16.39 ±7.35 nmol/l, p = 0.017). The univariate regression for MACEs group indicated that the LDL-TG (b = 0.813, HR = 2.254, 95% CI: 1.454-3.494, p < 0.001), older age, sex and other factors were a significant risk for MACEs. Furthermore, in the adjusted Cox model showed that only higher baseline LDL-TG (b =0.512, HR = 1.669, 95% CI: 1.013-2.748, p = 0.044) and older age (b = 0.062, HR = 1.064, 95% CI: 1.034-1.094, p < 0.001, Table IV) were still predictors for MACEs.

CONCLUSIONS: Higher baseline LDL-TG closely associated with MACEs and it is a moderate and independent predictive factor for MACEs.

Free PDF Download

To cite this article

X.-H. Ding, P. Ye, X.-N. Wang, R.-H. Cao, X. Yang, W.-K. Xiao, Y. Zhang, Y.-Y. Bai, H.-M. Wu
The predictive value of baseline LDL-TG level on major adverse cardiovascular events in a followed up cohort population

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 5
Pages: 1060-1064